The Board of Directors of CHO Pharma Inc. recently approved issuance of up to 30 million common shares with the participation of Fubon Financial Holdings and a number of major technology companies. The company's Chairman, Dr. Chao-Long Chen, said that the company's R&D capabilities and drugs have gradually demonstrated their value over the past decade, with clinical data from the Phase I/IIa clinical trial of its first glycoengineered homogenous antibody new drug, H01, being released in the third quarter of this year. This year's priority of CHO Pharma is to focus on licensing with a multinational pharmaceutical company. 

Dr. Chen said that H01, the first glycoengineered homogenous antibody drug, has been approved by the U.S. FDA and the Taiwan's FDA for Phase I/IIa clinical trials, and clinical data are expected to be released in the third quarter of this year.

In view of the series of R&D achievements, CHO's president Dr. Chung-Yi Wu emphasized that the most important goal of CHO is to complete the licensing with international pharmaceutical companies or to conduct subsequent development cooperation.

In addition to H01, CHO also has a single strain of humanized anti-cancer antibody A04, which can identify SSEA-4, and a vaccine against the pathogenic bacterium Klebsiella pneumoniae (V08), which is under development.

Wu added that the initial indication for the glycoside-based H01 is lymphoma treatment, and Phase I clinical trials have been conducted at various doses, and the information disclosed by the company so far indicates a positive safety result.

In addition, the company's core technology platform, CHOptimax, has been used to develop the hot ADC drug process technology. According to Wu, the company's competitive advantage is that it can significantly shorten the ADC development process.

Wu said that CHOptimax is a revolutionary glycoengineering technology for homogeneous antibody that utilizes exclusive patented key enzyme to rapidly produce specific antibody with the best glycan structure. This technological breakthrough has simplified a complex process and reduced production costs to a new commercial milestone.